We serve Chemical Name:N-(4-Bromobenzyl)cyclopropanamine CAS:70894-73-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:N-(4-Bromobenzyl)cyclopropanamine
CAS.NO:70894-73-4
Synonyms:N-(4-Bromobenzyl)cyclopropanamine;Benzenemethanamine, 4-bromo-N-cyclopropyl-;N-Cyclopropyl-4-bromo-benzylamine
Molecular Formula:C10H12BrN
Molecular Weight:226.113
HS Code:2921499090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:292.2±15.0 °C at 760 mmHg
Density:1.4±0.1 g/cm3
Index of Refraction:1.605
PSA:12.03000
Exact Mass:225.015305
LogP:2.66
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like N-(4-Bromobenzyl)cyclopropanamine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,N-Cyclopropyl-4-bromo-benzylamine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,N-Cyclopropyl-4-bromo-benzylamine Use and application,N-(4-Bromobenzyl)cyclopropanamine technical grade,usp/ep/jp grade.
Related News: Liam McHale, site director for Charles River Ballina said: “We are incredibly proud of the transformational changes we have implemented on site and the role that Charles River has played in supporting the safe and timely rollout of AstraZeneca’s COVID-19 vaccine. (S)-4-(4-But-2-ynyloxy-benzenesulfonyl)-[1,4]thiazepane-3-carboxylic acid hydroxyamide manufacturers “We’re going to further invest in research and development to continue to build our pipeline of products, in a more sophisticated way,” he says, holding up a pocket-sized wearable device and a tiny insulin pen to his screen’s camera. “We really believe in this business for the next—we hope—70 years.” [3-Isopropyl-1,2-diphenyl-5-((E)-styryl)-imidazolidin-4-yl]-phenyl-methanone suppliers SARS-CoV-2 has evolved mutations that severely compromise the neutralizing activities of multiple IgG monoclonal antibodies, including those under clinical trials and authorized for emergency use.
Therefore, developing new antibody therapies that can overcome these challenges is an urgent unmet need, and we are pleased with the data published today,” An said.
“Synergizing the strengths of multiple institutions from academia and industry is the key to the rapid translation from ideas to therapeutic candidates.
This is another example of such success. The cross-institutional and academic-industry collaborations should be expanded to other disease indications,” said Pei-Yong Shi, PhD, professor and co-senior author of the study from the Department of Biochemistry and Molecular Biology at UTMB Health.
This antibody has been licensed to biotech partner IGM Biosciences for drug development.
“The ability to use potently neutralizing IgM antibodies against SARS-CoV-2 with broad coverage of VOCs, VOIs, and viral escape mutants, is a very exciting application of the IGM platform,” said Fred Schwarzer, CEO of IGM Biosciences.
“We are grateful to our collaborators at UTHealth, UTMB Health, and our scientists at IGM for the exceptional work described in Nature today. α-methyl-α-(2-((2,3-dimethoxyphenyl)methoxy)ethyl)-1,4-benzodioxin-2,3-dimethanol vendor & factory.
Therefore, developing new antibody therapies that can overcome these challenges is an urgent unmet need, and we are pleased with the data published today,” An said.
“Synergizing the strengths of multiple institutions from academia and industry is the key to the rapid translation from ideas to therapeutic candidates.
This is another example of such success. The cross-institutional and academic-industry collaborations should be expanded to other disease indications,” said Pei-Yong Shi, PhD, professor and co-senior author of the study from the Department of Biochemistry and Molecular Biology at UTMB Health.
This antibody has been licensed to biotech partner IGM Biosciences for drug development.
“The ability to use potently neutralizing IgM antibodies against SARS-CoV-2 with broad coverage of VOCs, VOIs, and viral escape mutants, is a very exciting application of the IGM platform,” said Fred Schwarzer, CEO of IGM Biosciences.
“We are grateful to our collaborators at UTHealth, UTMB Health, and our scientists at IGM for the exceptional work described in Nature today. α-methyl-α-(2-((2,3-dimethoxyphenyl)methoxy)ethyl)-1,4-benzodioxin-2,3-dimethanol vendor & factory.
